BioVie Inc.

NasdaqCM BIVI

BioVie Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

BioVie Inc. Revenue is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

BioVie Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
BioVie Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
BioVie Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00, a 0.00% change year over year.
BioVie Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.00, a 0.00% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqCM: BIVI

BioVie Inc.

CEO	Mr. Cuong Viet Do M.B.A.
IPO Date	Sept. 18, 2020
Location	United States
Headquarters	680 West Nye Lane
Employees	14
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Key trends

Past 5 years